The elimination of high-level executive roles at Kronos Bio could be seen as a cost-saving measure, which might be positively received by investors in the short term. However, the removal of key leadership positions such as the CMO and CSO could also lead to concerns about the company's long-term strategic direction and its ability to innovate and manage operations effectively. The net impact on the stock price is uncertain, hence the neutral score.